This text is provided for reference. The official version is published by the Turkish Medicines and Medical Devices Agency (TİTCK).
Section I – Introduction and Scope
1.1. Introduction
1.1.1. Purpose
The purpose of a benefit-risk assessment is to determine whether there is sufficient evidence to show that the benefits of a product continue to outweigh its risks. This guideline has been prepared to guide marketing authorisation holders so that post-marketing benefit-risk assessments of medicines are carried out consistently and transparently and decision-making is facilitated. When meeting the requirements of this guideline, the comments and examples in the benefit-risk assessment template of Module X – Pre-marketing Benefit-Risk Assessment may be used.
Although the information in this document includes sections that can be used in the Periodic Safety Update Report (PSUR) and the Periodic Benefit-Risk Evaluation Report (PBRER), it is different from them (see Annex 1).
Section II – Structures and Processes
2.1. Conducting a benefit-risk assessment in the post-marketing period
This guideline outlines how to organise the information generally requested by the Agency as part of a benefit-risk assessment. Depending on the situation, the Agency may make additional requests. The marketing authorisation holder to whom the request is addressed is responsible only for providing evidence supporting the benefit-risk assessment of its own medicine. If the Agency is assessing the benefit-risk of a wider group of medicines, for example with the same active substances, each marketing authorisation holder will be subject to the same requirements for its own medicines. The information below summarises what is recommended for each section of the assessment.
2.1.1. Background information
This section describes background information on the medicine, including its use, any previous safety interventions and the diseases/conditions for which it is indicated. It identifies, or refers to, other possible alternatives from the same therapeutic group that are compared or discussed in the benefit-risk assessment, and their place in patient treatment.
2.1.1.1. Purpose
This section gives a brief overview of the main issues that led to the request for a benefit-risk assessment.
2.1.1.2. Product information
This section describes the medicine under assessment. The information may include the indications approved in Türkiye, class information, and formulation and/or labelling information relevant to the safety risk under review (contraindications, adverse reactions, etc.). Other indications authorised by competent authorities in other countries should also be included in this section.
2.1.1.3. Regulatory history
This section describes the regulatory history of the product, including its current regulatory and marketing status in Türkiye and with the regulators of other countries where it is authorised, and its date(s) of authorisation (international and in Türkiye).
2.1.1.4. Current risk minimisation strategies
This section provides information on previous and current risk mitigation strategies in place up to the benefit-risk assessment. These may include, but are not limited to, the labelling in the latest Turkish product monograph, all current educational materials and any risk communications that may have been published.
Where applicable, key differences between the labelling in Türkiye and in other International Council for Harmonisation (ICH) members should be highlighted. Safety issues addressed through past regulatory interventions in Türkiye and other countries should be listed.
2.1.1.5. Exposure estimates
This section contains exposure information:
- For international and Türkiye-specific data, an explanation of how exposure was calculated should be given, including:
- The data used
- How the data were used
- The start and end dates used for the calculation
- Exposure in Türkiye should be compared with international exposure, drawing attention to any relevant confounding and/or bias that may have affected exposure rates.
2.1.1.6. Information on the disease(s) or condition(s)
This section describes the underlying diseases/conditions for which the medicine is used and should include information specific to Türkiye. It may include, for example:
- Signs and symptoms
- The population to which the indication applies
- Pathophysiology
- Epidemiology (including risk factors as well as incidence and prevalence rates in Türkiye and internationally)
This section should also include a short description of how the disease/condition is managed, including treatment options for individual patients/populations and the uncertainties of the disease and its treatments.
2.1.1.7. Other treatment alternatives
This section provides background information on other relevant medical treatments, including the benefits and risks listed in their summaries of product characteristics. This information is for comparison within the benefit-risk assessment. Other topics that may be included, where relevant, are barriers to safe and effective use or patient preference. This information should be included for relevant medical treatments authorised for use in Türkiye. Any off-label treatments used for the condition should also be discussed to provide additional context.
2.2. Assessment of benefit
2.2.1. Characterisation of benefits
This section describes:
- The intended benefits of the product for the approved indication
- For example, preventing disease, treating an acute condition to reduce the risk of a serious outcome, or reducing or stabilising a chronic disorder
- Possible effects on related, subsequent or more serious conditions
- Information on efficacy from pre- or post-marketing evidence;
- This should include information on the strength of the evidence for efficacy, for example data from clinical studies, systematic reviews and meta-analyses (of clinical trials or observational studies) and/or data from therapeutic effectiveness studies. References such as Cochrane may be used when discussing the quality or strength of the evidence.
- Information on real-world effectiveness from post-marketing evidence.
Add the following to this section, in no particular order:
- The population to which the indication applies
- Known/relevant pharmacological properties of the medicine and its metabolites
- Identification of trends, patterns and/or correlations of the benefits assessed
- Consistency of the data
- Identification of bias and confounding factors
- Comparisons between efficacy in clinical trials and post-marketing (real-world) effectiveness
- The role of the medicine in providing a benefit in the context of medical practice in Türkiye
- Primary and secondary efficacy and therapeutic outcomes (endpoints)
- Expected or potential benefits
- Improvements in patient-reported outcomes
- Improvements in adherence, persistence and/or ease of use
2.2.2. Discussion of comparative benefits
Where information is available, this section can be useful in providing context for the benefit-risk assessment, as it compares the efficacy/real-world effectiveness of the medicine (or its class, where applicable) in clinical trials with:
- No intervention
- Other conventional treatments or interventions
A description of the pre- or post-marketing evidence of comparative efficacy/real-world effectiveness benefits for the approved indication(s) should be included. In addition to Phase I–III clinical trials, the description may include:
- Phase IV clinical trials (where applicable)
- Systematic reviews and meta-analyses of observational studies
- Comparative therapeutic effectiveness observational studies
- The data selection process
- Quality of the evidence
Studies of products not included in the analysis should be clearly identified, and the reasons for their exclusion clearly presented.
Where there is a known benefit relative to comparator products or other available treatments, provide information on comparative efficacy, which should include evidence on the uniqueness of the product or on a restricted population, for example:
- Study design and methodologies
- Statistical and clinical significance of the results
- Adequacy of statistical methods and analyses
- Consistencies and inconsistencies between efficacy and real-world effectiveness data in pre-marketing submissions
- The relationship between short- and long-term benefits
- Efficacy in clinical trials versus real-world effectiveness
- Exposure-response relationships
- Methodologies for synthesising research evidence
- Adherence to best practice for conducting systematic reviews of observational studies (e.g. Cochrane)
- Adequacy of the methodologies for combining data from different observational designs
- Methodologies for combining observational data with randomised clinical trial data
Other factors to consider in the analysis of comparative benefits are:
- Adverse drug reactions / validated signals
- Important identified risks
- Important potential risks / pharmacological class effects
- Decline in positive patient-reported outcomes
- Reduced adherence, persistence and/or ease of use
- Lack of efficacy
2.3. Assessment of risk
2.3.1. Characterisation of risk
This section defines the issues to be discussed, focusing on the issue that triggered the benefit-risk assessment. Provide a short medical summary of the issue (identified risk) with appropriate information on epidemiology, clinical features, medical seriousness, associated outcome (reversibility, morbidity, mortality), duration, preventability, predictability, measurability, capacity to monitor the issue, uncertainties in the benefit-risk assessment and, if not presented earlier, known risk factors. Important potential risks / missing information should also be defined.
Address only potential risks that lead to undesirable clinical outcomes and for which there is scientific evidence to suspect a possible causal association with the medicinal product, but where there is currently insufficient evidence to conclude that the association is causal. Important potential risks are potential risks that, once further characterised and confirmed, would have an impact on the benefit-risk balance of the medicinal product. If there is a scientific rationale that an adverse clinical outcome may result from off-label use, use in populations not studied or long-term use of the product, the adverse reaction should be considered a potential risk and, if considered important, included in the list of safety concerns as an important potential risk. Important potential risks usually require further evaluation as part of the pharmacovigilance plan.
Missing information relevant to risk management planning refers to gaps in knowledge about the safety of the medicine for a certain anticipated use (e.g. long-term use) or for use in particular patient populations, for which there is insufficient knowledge to determine whether its safety profile differs from that characterised so far. The absence of data (e.g. the exclusion of a population from clinical studies) does not automatically constitute a safety concern. Instead, risk management planning should focus on situations that may differ from the known safety profile.
The evidence on the issue (identified risk) should be described and critically analysed, starting with the most relevant evidence. The type of evidence may depend on the nature, incidence and/or severity of the adverse event. Where more than one type of evidence is available, it is recommended to present higher-quality evidence first and then move to lower levels of evidence. Discuss the validity of the evidence, which may include:
Meta-analyses and systematic reviews:
- Data source and type (briefly describe the search strategies/terms used for the literature)
- Study design and methodologies, including data source, selection criteria, weighting, risk differences or rate differences (if any), etc.
- Statistical and clinical significance of the results (where possible and meaningful)
- Limitations in study design, conduct or interpretation
Clinical trial data, especially Phase IV studies:
- Data source and type (briefly describe the search strategies/terms used for the literature)
- Study design and methodologies, including study quality, with information such as the endpoints used, duration of treatment and follow-up, and discontinuation rates
- Incidence/prevalence of the safety issue in clinical trials compared with placebo or other treatments
- Statistical and clinical significance of the results
- Consistency between studies
- Study selection process
- Limitations of the clinical trial data (e.g. sample sizes, excluded populations, duration of follow-up)
Observational studies:
- Data source and type (briefly describe the search strategies/terms used for the literature)
- Study design and methodologies, including study quality, with information such as the endpoints used, duration of treatment and follow-up
- Frequency/prevalence of the safety issue
- Clinical/scientific significance of the measure of risk
- Clinical/scientific validity of the study/studies, including methods to correct for confounding factors such as potential biases and missing data
Adverse drug reaction reports:
- Data source and type: spontaneous post-marketing adverse drug reaction (ADR) reports grouped by System Organ Class (SOC) or by the Medical Dictionary for Regulatory Activities (MedDRA) classification scheme
- Reporting period, search strategies and/or Standardised MedDRA Query (SMQ) terms
- Number, nature and outcome of (relevant) serious cases
- Trends, patterns and/or correlations of ADRs in relevant subgroups (e.g. age, sex, dose, predisposing risk factors, latency, duration of treatment, demographics, concomitant medicines, underlying diseases, overdose and/or food or drug interactions, and incidence/prevalence in the unexposed population)
- Summary of important case reports
- Causality assessment of selected cases
- Where possible, quantitative analyses of the association (e.g. reporting rate, proportional reporting ratio, reporting odds ratio, information component (IC) & IC025)
- Limitations of ADR reports and quantitative analyses (e.g. quality of reports, reporting rate, missing information, data-mining assumptions, validity).
2.3.2. Considerations on the issue (identified risk)
This section summarises the evidence on the safety issue. The discussion may include:
- Relevant pharmacological properties of the medicine and its metabolites (e.g. known/proposed mechanism(s) of action, possible class effect);
- Overdose of the medicine
- Susceptible/sensitive populations, including pharmacogenomics
- Relevant exposure/use data
- Approved use vs. off-label use
- Administration or treatment issues related to the medicine
- The quantitative strength of the association between use of the medicine and the identified safety issue;
- Evaluate the strength and quality of the evidence. References such as Cochrane or GRADE may be used as appropriate.
2.3.3. Discussion of comparative risks
This section can be useful in providing context for the benefit-risk assessment, as it compares the issue(s) (identified risk) of the medicine (or its class, where applicable) with risk issues associated with the following (if information is available):
- Other conventional treatments
- Surgical treatments / other interventions
- No intervention
- Other considerations
2.4. Assessment of the benefit-risk profile
2.4.1. Summary and analysis of the benefit-risk profile for the identified risk
This section provides context and justification for the overall conclusion on the benefit-risk profile of the product. It should include a summary of the key benefits and key risks of the medicine, listed in order of priority, with supporting explanation where relevant. This section should also compare the benefits and risks of the product when used under the approved indications for each issue, from sources such as:
- Meta-analyses and systematic reviews
- Clinical trial data, including Phase IV studies
- Observational studies
- Adverse drug reaction reports (international sources first, then sources from Türkiye)
The quality of the evidence should be addressed in this section (for example, if a well-designed Phase IV study is being compared with a poorly designed meta-analysis). The discussion should distinguish between the data and the value judgements used to interpret the degree of benefit against the degree of harm, and should also include the impact of uncertainty on the assessment. References may be used as appropriate, e.g. Cochrane.
2.4.2. Summary and analysis of the benefit-risk profile for potential risks
If the product has important potential risks, assess whether the benefit-risk profile is affected when these risks are taken into account.
2.4.3. Quantitative benefit-risk analysis
Specific quantitative or semi-quantitative methodologies are not currently required for benefit-risk assessments; however, they may be included in submissions to support the benefit-risk assessment. A detailed description of the methodologies, software, references and data analysed should be attached. Discuss the results of any quantitative or semi-quantitative methodology used to perform a benefit-risk assessment of the medicine. Add a short justification of why each methodology was used.
2.4.4. Context of the benefit-risk analysis
This section should describe how the known benefits and risks of the product at the time of authorisation have evolved compared with current information, such as new risk data or comparison with newer medicines. Similar parameters and outcome measures should be used where possible. Factors to consider may include:
- Benefits and risks in the context of current medical practice
- Changes in what is known about the benefits and risks of the product
- Limitations of the benefit-risk assessment (e.g. important uncertainties or unknowns).
2.5. Conclusions and risk mitigation options
2.5.1. Conclusions
Summarise the conclusion reached through the benefit-risk analysis of the medicine, with a short justification stating whether, and if so how, the overall benefit-risk profile of the medicine has changed.
2.5.2. Risk minimisation options
Where applicable, describe possible risk minimisation options if the overall benefit-risk profile has changed. These measures may consist of routine and/or additional risk minimisation measures.
Routine risk minimisation activities
Routine risk minimisation activities are those that apply to every medicine. They relate to:
- The summary of product characteristics (SmPC),
- Labelling on the immediate and outer packaging,
- The patient information leaflet (PL),
- Pack size,
- The legal status of the medicine.
Even the formulation itself can play an important role in minimising the risk of the product.
SmPC and PL
The SmPC and PL, which inform healthcare professionals and patients about medicines and have a controlled, standard format, play an important role in minimising risk.
Both provide routine risk minimisation recommendations; however, the SmPC and PL can convey two types of message:
- Routine risk communication messages: usually found in section 4.8 of the SmPC or section 4 of the PL; these messages communicate the undesirable effects of the medicinal product to healthcare professionals and patients so that an informed treatment decision can be made.
- Routine risk minimisation activities recommending specific clinical measures to address the risk: usually found in sections 4.2 and 4.4 of the SmPC, but may also appear in sections 4.1, 4.3, 4.5, 4.6, 4.7 and 4.9 and in sections 2 and 3 of the PL. Examples of warning and precaution messages and recommendations in the SmPC:
- Performing a test before starting treatment.
- Monitoring laboratory parameters during treatment.
- Monitoring signs and symptoms.
- Adjusting the dose or stopping treatment when adverse events are observed or laboratory parameters change.
- Applying a washout procedure after treatment is stopped.
- Providing contraception recommendations.
- Prohibiting the use of other medicines while taking the product.
- Treating or preventing risk factors that may cause the adverse event.
- Recommending long-term clinical follow-up to identify delayed adverse events at an early stage.
Pack size
Since each pack size is authorised specifically for the medicine, planning the number of dosage units in each pack and determining the range of available pack sizes can be considered a routine risk management activity. In theory, controlling the number of dosage units ensures that the patient sees a healthcare professional at defined intervals, increasing the chance of testing and shortening the time the patient goes without examination.
A small pack size is useful if overdose or misuse is considered an important risk.
Legal status
Controlling the conditions under which a medicine may be made available on the market makes it possible to reduce the risks associated with its use or misuse. The marketing authorisation should include the conditions and restrictions imposed on the supply and use of the medicine, and even the details of the conditions under which it may be made available to patients. This is commonly called the "legal status" of the medicine. It generally includes whether the medicine is subject to prescription. It may also restrict where the medicine can be administered (e.g. in a hospital) or who may prescribe it (e.g. a specialist).
Prescription medicines can be classified as medicines subject to special prescription and medicines subject to restricted prescription for use in certain specialised settings.
Medicines subject to restricted prescription
This can be used to control which specialist initiates the medicine, who may write maintenance prescriptions, and under which conditions the medicine is supplied or used. When classification as subject to restricted prescription is considered, the following factors should be taken into account:
- Because of its pharmaceutical characteristics or novelty, or in the interest of public health, the medicine may be reserved for treatments that can only be followed in a hospital setting.
- The medicine may be used to treat conditions that must be diagnosed in a hospital setting or in institutions with adequate diagnostic facilities, although administration and follow-up may be carried out elsewhere.
- The medicine is intended for outpatient use, but because its use may cause very serious adverse reactions, the prescription must be written by a specialist and special supervision is required throughout treatment.
Medicines subject to special prescription
The following factors are taken into account when classifying a medicine as subject to special prescription:
- The medicine contains a substance classified as a narcotic, psychotropic or precursor substance under international conventions such as the United Nations Conventions of 1961, 1971 and 1988.
- Incorrect use of the medicine carries a substantial risk of abuse, leads to addiction or carries a risk of misuse for illegal purposes.
- As a precautionary measure owing to its novelty or properties, the medicine contains a substance that could belong to the group described in the previous paragraph.
Additional risk minimisation activities
Additional risk minimisation activities should only be proposed when they are needed for the safe and effective use of the medicine. If additional risk minimisation activities are proposed, the reasons why they are necessary should be detailed and justified. The need to continue such measures should be reviewed periodically (see Good Pharmacovigilance Practices (GVP) Guideline Module IX – Risk Minimisation Measures: Selection of Tools and Effectiveness Indicators, Section II).
2.5.3. Routine post-marketing benefit-risk assessment
PBRERs are one of the most fundamental tools for the post-marketing benefit-risk assessment of medicines. The practices and requirements for preparing and submitting PBRERs are set out in Good Pharmacovigilance Practices (GVP) Guideline Module III – Periodic Benefit-Risk Evaluation Report.
2.6. Actions to be taken by the Agency
Following the benefit-risk assessment by the marketing authorisation holder, the Agency, if it considers it necessary, initiates the appropriate actions from the following and notifies the marketing authorisation holder:
- Requiring a post-authorisation safety study.
- Implementing measures to minimise the risk.
- Suspension or revocation of the marketing authorisation, or refusal of its renewal.
- Prohibiting the supply of the medicine.
- Changes to the medicine information, such as adding a new contraindication, reducing the recommended dose or restricting the indication.
Annex 1 – Sections of the PSUR or PBRER that can be used or reused
| Benefit-risk assessment | Periodic Safety Update Report (PSUR) | Periodic Benefit-Risk Evaluation Report (PBRER) |
|---|---|---|
| Background information: product information, use, exposure estimates, previous safety interventions, disease(s)/condition(s) and other treatment options | Sections 1, 3, 4, 5 | Sections 1, 3, 4, 5 |
| *Characterisation of the safety issue: evidence and analysis of the safety issue, including medical history | Not included | Not included |
| Characterisation and assessment of benefits: evidence of efficacy and real-world effectiveness, relevant pharmacological properties of the product and metabolites, comparison with alternative treatments supported by data from clinical and observational studies | Not included | Section 17 (enhanced analysis required) |
| *Characterisation and assessment of risk(s): relevant risks identified before and after marketing | Not included | Sections 13, 15, 16 |
| Assessment of the benefit-risk profile: provides justification and context for the overall conclusion on the benefit-risk profile of the product; quantitative or semi-quantitative analysis required | Not included | Section 18 (enhanced analysis required) |
| Final conclusions and risk minimisation options: follow-up measures including impact analysis | Not included | Section 19 (enhanced analysis required) |
*Information may be found in the product's Risk Management Plan (RMP).
References
- Format and content for post-market drug benefit-risk assessment in Canada, Guidance document, Health Canada, February 2019. https://www.canada.ca/content/dam/hc-sc/documents/services/publications/drugs-health-products/content-drug-benefit-risk-assessment/content-drug-benefit-risk-assessment-eng.pdf
Revision history
| Revision No | Revision date | Reason and explanation |
|---|---|---|
| 1 | 15.11.2022 | Format updated. |
| 2 | 30.11.2022 | Definition of potential risk added and the summary of the benefit-risk profile for potential risks explained. Routine risk minimisation activities detailed. |
| 3 | 20.01.2023 | Section 2.6 "Actions to be taken by the Agency" added. The reference used in preparing the guideline added. |
